For more information about Intercept, please contact Mark Pruzanski, M.D., or Barbara Duncan, both of Intercept Pharmaceuticals, at 1-646-747-1000.

If you liked this article you might like

Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Clovis Sell-Off May Be Overdone